Oppenheimer on Harmony Biosciences Holdings Inc. (HRMY): 'WAKIX Approved for EDS in Pediatric Narcolepsy, Small But Meaningful Commercial Opportunity'
Tweet Send to a Friend
Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $56.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
